Review





Similar Products

alphalisa signal  (Revvity)
96
Revvity alphalisa signal
Alphalisa Signal, supplied by Revvity, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphalisa/EnVision+XCite+multimode+plate+reader/pmc13114140-83-1-9
Average 96 stars, based on 1 article reviews
alphalisa signal - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
alphalisa hts hek 293t cells  (ATCC)
99
ATCC alphalisa hts hek 293t cells
Alphalisa Hts Hek 293t Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphalisa/293T/pm41068187-193-12-20
Average 99 stars, based on 1 article reviews
alphalisa hts hek 293t cells - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
alphalisa labelled 6e10  (Covance)
86
Covance alphalisa labelled 6e10
Alphalisa Labelled 6e10, supplied by Covance, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphalisa/anti+primary/pmc13254515-22-8-11
Average 86 stars, based on 1 article reviews
alphalisa labelled 6e10 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
alphalisa labelled 12f4  (Covance)
86
Covance alphalisa labelled 12f4
Alphalisa Labelled 12f4, supplied by Covance, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphalisa/12f4+alphalisa+anti+labelled/pmc13254515-18-7-10
Average 86 stars, based on 1 article reviews
alphalisa labelled 12f4 - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
alphalisa readings  (BMG Labtech)
99
BMG Labtech alphalisa readings
G protein-coupled receptor 35 (GPR35) activation reduces c-Src and PI3K-Akt signaling pathways in mature osteoclasts. Quantification of phosphorylated (A) c-Src (pSrc), (B) Akt1/2/3 (pAkt), and (C) p38 (p-p38) measured by <t>AlphaLISA</t> in osteoclasts exposed to vehicle or GPR35 agonists with or without GPR35 antagonist ML145. (D-E) Quantification of (D) c-Src and (E) Akt1/2/3 phosphorylation in mature osteoclasts transfected with scrambled or GPR35 siRNA exposed to vehicle or GPR35 agonist, TC-G 1001. Data in all panels was normalized to GAPDH as a housekeeper control. Each point represents an independent donor in all panels. The gray line denotes mean in panels a, B, D and E and median in panel C. Statistical analyses were performed by one-way ANOVA with Holm-Šídák’s multiple comparisons test in panels A, B, D, and E and Kruskal–Wallis with Dunn’s multiple comparisons test in C. **** p < .0001, *** p < .001, ** p < .01, * p < .05.
Alphalisa Readings, supplied by BMG Labtech, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphalisa/PHERAstar+FSX/pmc12445851-62-0-8
Average 99 stars, based on 1 article reviews
alphalisa readings - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
alphalisa assay  (Biosynth Carbosynth)
93
Biosynth Carbosynth alphalisa assay
G protein-coupled receptor 35 (GPR35) activation reduces c-Src and PI3K-Akt signaling pathways in mature osteoclasts. Quantification of phosphorylated (A) c-Src (pSrc), (B) Akt1/2/3 (pAkt), and (C) p38 (p-p38) measured by <t>AlphaLISA</t> in osteoclasts exposed to vehicle or GPR35 agonists with or without GPR35 antagonist ML145. (D-E) Quantification of (D) c-Src and (E) Akt1/2/3 phosphorylation in mature osteoclasts transfected with scrambled or GPR35 siRNA exposed to vehicle or GPR35 agonist, TC-G 1001. Data in all panels was normalized to GAPDH as a housekeeper control. Each point represents an independent donor in all panels. The gray line denotes mean in panels a, B, D and E and median in panel C. Statistical analyses were performed by one-way ANOVA with Holm-Šídák’s multiple comparisons test in panels A, B, D, and E and Kruskal–Wallis with Dunn’s multiple comparisons test in C. **** p < .0001, *** p < .001, ** p < .01, * p < .05.
Alphalisa Assay, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphalisa/HBsAg+antibody/pm34267883__ml1c00228_si_001-149-8-18
Average 93 stars, based on 1 article reviews
alphalisa assay - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
alphalisa based inhibition assay  (Galectin Therapeutics)
86
Galectin Therapeutics alphalisa based inhibition assay
G protein-coupled receptor 35 (GPR35) activation reduces c-Src and PI3K-Akt signaling pathways in mature osteoclasts. Quantification of phosphorylated (A) c-Src (pSrc), (B) Akt1/2/3 (pAkt), and (C) p38 (p-p38) measured by <t>AlphaLISA</t> in osteoclasts exposed to vehicle or GPR35 agonists with or without GPR35 antagonist ML145. (D-E) Quantification of (D) c-Src and (E) Akt1/2/3 phosphorylation in mature osteoclasts transfected with scrambled or GPR35 siRNA exposed to vehicle or GPR35 agonist, TC-G 1001. Data in all panels was normalized to GAPDH as a housekeeper control. Each point represents an independent donor in all panels. The gray line denotes mean in panels a, B, D and E and median in panel C. Statistical analyses were performed by one-way ANOVA with Holm-Šídák’s multiple comparisons test in panels A, B, D, and E and Kruskal–Wallis with Dunn’s multiple comparisons test in C. **** p < .0001, *** p < .001, ** p < .01, * p < .05.
Alphalisa Based Inhibition Assay, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/alphalisa/alphalisa+assay+based+inhibition/bio_rxiv__2025__08__09__669500-110-26-14
Average 86 stars, based on 1 article reviews
alphalisa based inhibition assay - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


G protein-coupled receptor 35 (GPR35) activation reduces c-Src and PI3K-Akt signaling pathways in mature osteoclasts. Quantification of phosphorylated (A) c-Src (pSrc), (B) Akt1/2/3 (pAkt), and (C) p38 (p-p38) measured by AlphaLISA in osteoclasts exposed to vehicle or GPR35 agonists with or without GPR35 antagonist ML145. (D-E) Quantification of (D) c-Src and (E) Akt1/2/3 phosphorylation in mature osteoclasts transfected with scrambled or GPR35 siRNA exposed to vehicle or GPR35 agonist, TC-G 1001. Data in all panels was normalized to GAPDH as a housekeeper control. Each point represents an independent donor in all panels. The gray line denotes mean in panels a, B, D and E and median in panel C. Statistical analyses were performed by one-way ANOVA with Holm-Šídák’s multiple comparisons test in panels A, B, D, and E and Kruskal–Wallis with Dunn’s multiple comparisons test in C. **** p < .0001, *** p < .001, ** p < .01, * p < .05.

Journal: JBMR Plus

Article Title: G protein-coupled receptor 35 stimulation reduces osteoclast activity in primary human bone cells

doi: 10.1093/jbmrpl/ziaf131

Figure Lengend Snippet: G protein-coupled receptor 35 (GPR35) activation reduces c-Src and PI3K-Akt signaling pathways in mature osteoclasts. Quantification of phosphorylated (A) c-Src (pSrc), (B) Akt1/2/3 (pAkt), and (C) p38 (p-p38) measured by AlphaLISA in osteoclasts exposed to vehicle or GPR35 agonists with or without GPR35 antagonist ML145. (D-E) Quantification of (D) c-Src and (E) Akt1/2/3 phosphorylation in mature osteoclasts transfected with scrambled or GPR35 siRNA exposed to vehicle or GPR35 agonist, TC-G 1001. Data in all panels was normalized to GAPDH as a housekeeper control. Each point represents an independent donor in all panels. The gray line denotes mean in panels a, B, D and E and median in panel C. Statistical analyses were performed by one-way ANOVA with Holm-Šídák’s multiple comparisons test in panels A, B, D, and E and Kruskal–Wallis with Dunn’s multiple comparisons test in C. **** p < .0001, *** p < .001, ** p < .01, * p < .05.

Article Snippet: AlphaLISA readings were made on a PHERAstar FS (BMG Labtech, Aylesbury, United Kingdom) plate reader, and values for phosphorylated proteins normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) values.

Techniques: Activation Assay, Protein-Protein interactions, Phospho-proteomics, Transfection, Control

G protein-coupled receptor 35 (GPR35) mediated effects on bone resorption and signaling are maintained in osteoclast-osteoblast co-cultures. (A) Quantification of toluidine blue-stained resorption pits and trenches formed on bone slices by osteoclast-osteoblast co-cultures exposed to vehicle, TC-G 1001, or TC-G 1001 and the ML145 antagonist (B) quantification of tartrate-resistant acid phosphatase enzyme activity in conditioned media from osteoclast-osteoblast co-cultures exposed to GPR35 agonists or agonists with antagonist. (C-F) quantification of (C) phosphorylated c-Src, (D) phosphorylated Akt1/2/3, (E) phosphorylated NFκB, (F) phosphorylated cAMP response element-binding protein in osteoclast-osteoblast co-cultures exposed to GPR35 agonists or agonists with antagonist, measured by AlphaLISA. Each point represents an independent donor. The gray line denotes mean. Statistical analyses were performed by one-way ANOVA with Holm-Šídák’s multiple comparisons test for A-B and with Dunnett’s multiple comparisons test for C-F. **** p < .0001, *** p < .001, ** p < .01, * p < .05.

Journal: JBMR Plus

Article Title: G protein-coupled receptor 35 stimulation reduces osteoclast activity in primary human bone cells

doi: 10.1093/jbmrpl/ziaf131

Figure Lengend Snippet: G protein-coupled receptor 35 (GPR35) mediated effects on bone resorption and signaling are maintained in osteoclast-osteoblast co-cultures. (A) Quantification of toluidine blue-stained resorption pits and trenches formed on bone slices by osteoclast-osteoblast co-cultures exposed to vehicle, TC-G 1001, or TC-G 1001 and the ML145 antagonist (B) quantification of tartrate-resistant acid phosphatase enzyme activity in conditioned media from osteoclast-osteoblast co-cultures exposed to GPR35 agonists or agonists with antagonist. (C-F) quantification of (C) phosphorylated c-Src, (D) phosphorylated Akt1/2/3, (E) phosphorylated NFκB, (F) phosphorylated cAMP response element-binding protein in osteoclast-osteoblast co-cultures exposed to GPR35 agonists or agonists with antagonist, measured by AlphaLISA. Each point represents an independent donor. The gray line denotes mean. Statistical analyses were performed by one-way ANOVA with Holm-Šídák’s multiple comparisons test for A-B and with Dunnett’s multiple comparisons test for C-F. **** p < .0001, *** p < .001, ** p < .01, * p < .05.

Article Snippet: AlphaLISA readings were made on a PHERAstar FS (BMG Labtech, Aylesbury, United Kingdom) plate reader, and values for phosphorylated proteins normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) values.

Techniques: Staining, Activity Assay, Binding Assay